ArticleYonsei medical journal2026
Risk Analysis of Waiting-List Mortality in Heart Transplantation: A Multicenter Study in Korea.
Article in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThere are few national studies of waiting-list mortality for heart transplantation (HT) in Korea. Our multicenter study examined mortality on the HT waiting list and its associated risk factors. MATERIALS AND
methodsWe retrospectively analyzed 1101 consecutive patients who were wait-listed for HT between 2012 and 2017 in four centers. Time on the HT waiting list was defined as the time from initial wait-listing to delisting due to HT, death, or recovery. Subjects were censored at the time of transplantation or recovery.
resultsOf the whole cohort, 327 (29.7%) patients needed mechanical circulatory support (MCS) while on the waiting list, 314 (28.5%) were treated with extracorporeal membrane oxygenation (ECMO) as a bridge, and 13 (1.2%) were treated with a ventricular assist device (VAD) as a bridge. The waiting-list survival rate for ECMO-bridged patients was significantly lower than that for VAD-bridged or non-MCS-bridged patients. The waiting-list survival rate for patients with a status of 0 or 1 was significantly lower than for patients with a status of 2 or 3. Multivariate analysis revealed that the independent risk factors for waiting-list mortality were congenital heart disease and restrictive cardiomyopathy compared with dilated cardiomyopathy, status 0 compared with status 2 and 3, low hemoglobin, history of ventricular arrhythmia, high MELD-XI score, and ECMO bridging during the waiting period.
conclusionThis study showed that ECMO as a bridge to transplantation and status 0 were associated with significantly higher waiting-list mortality. Advanced end-organ damage at the time of listing was also found to be an independent risk factor for waiting-list mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.